Pioglitazone inhibits platelet function and potentiates the effects of aspirin: A prospective observation study
Thrombosis Research, 06/04/2012
Mongan J et al. - Pioglitazone inhibits platelet function and potentiates the inhibitory effects of aspirin.Methods
- 20 normal and 20 diabetic subjects were enrolled in a prospective study.
- On day 1, a blood sample was obtained at baseline and a second one after ingestion of 30mg of pioglitazone.
- PRP was prepared and platelet aggregation and release were evaluated using ADP, collagen and arachidonic acid as agonists.
- Subjects returned at 6–9days later after ingesting a single 81mg dose of aspirin and a third blood sample was obtained.
- The subjects then again ingested 30mg of pioglitazone and a fourth and final blood sample was obtained.
- Platelet aggregation and release were measured.
- PRP was incubated with thrombin to activate platelets, and the serum was separated and assayed for thromboxane B2, TGF β and CD40L.
- Pioglitazone alone did not affect aggregation with arachidonic acid.
- However, following ingestion of both aspirin and pioglitazone aggregation was significantly decreased compared to aspirin alone (P<0.0001).
- Pioglitazone also potentiated aspirin-induced inhibition of ATP release using either arachidonic acid or collagen.
- Following pioglitazone alone, TXB2 release was 32,719±3,585pg/ml which was significantly reduced compared to baseline (42,075±4,479, P=0.0004).
- Pioglitazone also potentiated the inhibition of TXB2 release by aspirin.